News & Updates

In the treatment of patients with nonresectable colorectal cancer (CRC) with liver metastases, liver transplantation may improve long-term survival outcomes especially when performed for those with favourable prognostic scoring, according to a study.

A recent study has found no amino acid substitutions associated with reduced sensitivity to bulevirtide (BLV) monotherapy, a hepatitis D/B virus (HDV/HBV) entry inhibitor, at baseline or week 24 in patients with virologic breakthrough after BLV treatment.

Magnetic resonance elastography demonstrates high accuracy in the noninvasive staging of liver fibrosis in patients with nonalcoholic fatty liver disease (NAFLD), reports a study.

Hepatic hypoxia-inducible lipid droplet associated protein (HILPDA) is predictive of survival in patients with nonalcoholic steatohepatitis (NASH)-driven hepatocellular carcinoma (HCC), according to a study.

Current estimates of nonalcoholic fatty liver disease (NAFLD) incidence across the world show an increasing trend, with 4,613 new cases per 100,000 person-years, reveals a study.

Minimal monitoring is feasible in patients with active hepatitis C virus (HCV) infection treated with sofosbuvir/velpatasvir (SOF/VEL), with high rates of sustained virologic response (SVR) reported, including in patients with novel HCV subtypes, according to new data from the phase IV MINMON study presented at IDDF 2023.

The combination of sofosbuvir, velpatasvir, and voxilaprevir (SOF/VEL/VOX) with or without ribavirin demonstrates efficacy for the retreatment of patients with hepatitis C virus (HCV) infection in whom prior direct-acting antiviral (DAA) treatment has failed, a study in Egypt has shown.